Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer

Alvanegh, Akbar Ghorbani; Ganji, Shahla Mohammad; Kamel, A. El; Tavallaie, Mahmood; Rafati, Alireza; Arpanaei, Ayyoob; Dorostkar, Ruhollah; Ghaleh, Hadi Esmaeili Gouvarchin

doi:10.1016/j.biopha.2021.111755

Cited by 12 publications

(6 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some tumors, such as multiple myeloma, preliminary basic studies and associated clinical works have explored the value of microRNAs as potential biomarkers [296]. In lung cancer, oncolytic virotherapy and nanotherapy have been used to deliver microRNAs into cancer cells, although they have not been included in cancer treatments so far [297]. Several clinical studies are evaluating the utility of miRNA-blood based analyses for the early detection of cancer, while others are investigating the prognostic and predictive value of these molecules [298].…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

et al. 2021

View full text Add to dashboard Cite

Embryonic stem cells (ESCs) have the extraordinary properties to indefinitely proliferate and self-renew in culture to produce different cell progeny through differentiation. This latter process recapitulates embryonic development and requires rounds of the epithelial–mesenchymal transition (EMT). EMT is characterized by the loss of the epithelial features and the acquisition of the typical phenotype of the mesenchymal cells. In pathological conditions, EMT can confer stemness or stem-like phenotypes, playing a role in the tumorigenic process. Cancer stem cells (CSCs) represent a subpopulation, found in the tumor tissues, with stem-like properties such as uncontrolled proliferation, self-renewal, and ability to differentiate into different cell types. ESCs and CSCs share numerous features (pluripotency, self-renewal, expression of stemness genes, and acquisition of epithelial–mesenchymal features), and most of them are under the control of microRNAs (miRNAs). These small molecules have relevant roles during both embryogenesis and cancer development. The aim of this review was to recapitulate molecular mechanisms shared by ESCs and CSCs, with a special focus on the recently identified classes of microRNAs (noncanonical miRNAs, mirtrons, isomiRs, and competitive endogenous miRNAs) and their complex functions during embryogenesis and cancer development.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The stability provided by OVs harbouring miRNAs is inferior to those provided by encapsulation strategies. However, the insertion of multiple copies of the desired miRNA, into the viral genome, could help to overcome this limitation ( 65 ).…”

Section: Delivering Therapeutic Mirnas With Ovsmentioning

confidence: 99%

Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs

St-Cyr

Penarroya²,

Daniel³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

MiRNAs (miRNA, miR) play important functions in the tumor microenvironment (TME) by silencing gene expression through RNA interference. They are involved in regulating both tumor progression and tumor suppression. The pathways involved in miRNA processing and the miRNAs themselves are dysregulated in cancer. Consequently, they have become attractive therapeutic targets as underscored by the plethora of miRNA-based therapies currently in pre-clinical and clinical studies. It has been shown that miRNAs can be used to improve oncolytic viruses (OVs) and enable superior viral oncolysis, tumor suppression and immune modulation. In these cases, miRNAs are empirically selected to improve viral oncolysis, which translates into decreased tumor growth in multiple murine models. While this infectious process is critical to OV therapy, optimal immunomodulation is crucial for the establishment of a targeted and durable effect, resulting in cancer eradication. Through numerous mechanisms, OVs elicit a strong antitumor immune response that can also be further improved by miRNAs. They are known to regulate components of the immune TME and promote effector functions, antigen presentation, phenotypical polarization, and varying levels of immunosuppression. Reciprocally, OVs have the power to overcome the limitations encountered in canonical miRNA-based therapies. They deliver therapeutic payloads directly into the TME and facilitate their amplification through selective tumoral tropism and abundant viral replication. This way, off-target effects can be minimized. This review will explore the ways in which miRNAs can synergistically enhance OV immunotherapy to provide the basis for future therapeutics based on this versatile combination platform.

show abstract

“…OVs have complicated working mechanisms. They kill TC and act as an “ in situ vaccination” by releasing a large number of tumor antigens to stimulate and expand the immune response [30] . Additionally, OVs can disrupt the tumor stroma, resulting in disruption of the tumor vasculature [31] .…”

Section: Promising Strategies Of Immunotherapy In Advanced or Metasta...mentioning

confidence: 99%

Current immune therapeutic strategies in advanced or metastatic non-small-cell lung cancer

Liu

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Immune escape mechanisms in non-small cell lung cancer (NSCLC) can disrupt every step of the anti-cancer immune response. In recent years, an increased understanding of the specific mechanisms fueling immune escape has allowed for the development of numerous immunotherapeutic treatments that have been introduced into the clinical practice. The advent of immunotherapy has dramatically changed the current treatment landscape of advanced or metastatic NSCLC because of its durable efficacy and manageable toxicity. In this review, we will first present a brief overview of recent evidence on immune escape mechanisms in NSCLC. We will then discuss the current promising immunotherapeutic strategies in advanced or metastatic NSCLC tumors.

show abstract

Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer

Cited by 12 publications

References 81 publications

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs

Current immune therapeutic strategies in advanced or metastatic non-small-cell lung cancer

Contact Info

Product

Resources

About